Remix Therapeutics Announces Participation in Jefferies 2024 Healthcare Conference

WATERTOWN, Mass., May 28, 2024 /PRNewswire/ — Therapeutic Remix (Remix), a clinical-stage biotechnology company developing small molecule therapies to modulate RNA processing and address underlying disease drivers, today announced that its management team will host one-on-one meetings with investors during the Jefferies Healthcare Conference which will take place on Tuesday, June 4, 2024 in New York.

Remix Therapeutics (PRNewsfoto/Remix Therapeutics)

For investors interested in scheduling a one-on-one meeting with the Remix management team, please contact your Jefferies representative.

About Remix Therapeutics
Remix Therapeutics is a clinical-stage biotechnology company developing novel small molecule therapeutics designed to reprogram RNA processing and treat diseases. The REMaster technology platform facilitates the identification of RNA processing patterns, leveraging these learnings to modulate gene expression. Remix’s innovative therapeutic approach has the potential to change the way genes are read from the genome, correcting, enhancing or eliminating the genetic message, thereby addressing disease-causing factors at their origin. origin. For more information, visit

Cision View original content to download multimedia:

SOURCE Therapeutic Remix